Fred Powell, Executive Vice President and Chief Financial Officer
Mr. Powell joined the Company in November of 2016 as Senior Vice President and Chief Financial Officer. Prior to joining Antares, from 2012 until 2016 Mr. Powell served as Vice President and Chief Financial Officer for Celator Pharmaceuticals, which was a publicly traded biopharmaceutical company engaged in the development of a portfolio of cancer therapies. At Celator, he was responsible for the Company’s accounting, corporate finance and financial planning functions. From 2011 until 2012, Mr. Powell was the chief financial officer of OraPharma, Inc. where he helped develop and grow the specialty healthcare company. Mr. Powell was chief financial officer of BMP Sunstone Corporation, a publicly traded U.S. specialty pharmaceutical company from 2005 until 2011. Mr. Powell also held senior finance and administration positions at Eximias Pharmaceutical Corporation, Innaphase Corporation and ERT. Mr. Powell began his career with KPMG Peat Marwick and is a 1983 graduate of Penn State University.
Peter J. Graham ESQ., Executive Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary
Mr. Graham joined the Company in July 2015 as Senior Vice President, General Counsel, Chief Compliance Officer, Human Resources and Corporate Secretary and has almost 20 years of legal and executive management experience in publicly and privately held pharmaceutical and medical device companies. From 2010 until 2015, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources for Delcath Systems, Inc. (NASDAQ: DCTH), a late stage clinical development company focused on cancers of the liver. From 2008 until 2010, Mr. Graham was Vice President, General Counsel and a member of the Executive Committee of ACIST Medical Systems, Inc., a subsidiary of Bracco, SpA., a global company specializing in cardiovascular and diagnostic imaging solutions. Prior to ACIST, Mr. Graham spent 11 years at E-Z- EM, Inc. (NASDAQ: EZEM), a global medical device and pharmaceutical company specializing in CT and MR imaging solutions serving as Senior Vice President, Chief Legal Officer, Global Human Resources and Secretary. From 1997 until 2004, Mr. Graham also served as General Counsel and Corporate Secretary for AngioDynamics, Inc. (NASDAQ: ANGO)(then a wholly owned subsidiary of EZEM), a leading provider of interventional medical devices. Mr. Graham earned his J.D. at Yeshiva University's Benjamin N. Cardozo School of Law in 1995,and his B.A. in Political Science at the University of Wisconsin-Madison.
Peter Sadowski, Ph.D., Senior Vice President, Technology Portfolio and Intellectual Property
Dr. Sadowski joined Medi-Ject Corporation, a predecessor company to Antares Pharma, in March 1994 as Vice President, Product Development. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. In 2009 he was promoted to Senior Vice President and General Manager, Parenteral Products Group. Prior to joining the Company, Dr. Sadowski led product development teams at Molecular Genetics, Inc., GalaGen, Inc., and American Biosystems, Inc. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota.
John J. Howarth, Vice President of Corporate Affairs
Mr. Howarth joined the Company in February 2012 as Vice President of Corporate Affairs. Prior to joining the Company, Mr. Howarth was employed at King Pharmaceuticals as Vice President of Investor Relations, joining the company through King’s acquisition of Alpharma. Prior to King Pharmaceuticals, Mr. Howarth held senior leadership positions spanning 25 years in investor and media relations at KOS Pharmaceuticals and Elan Corporation, and positions of increasing responsibility in finance and corporate development at Warner Lambert Company. Mr. Howarth received his B.S. degree in Accounting from Boston College and his M.B.A. in Finance from Seton Hall University.
Patrick Madsen, Senior Vice President, Operations
Mr. Madsen joined the Company in November 2010 as Vice President of Product Development, Parenteral Products Division. Prior to joining the Company, Mr. Madsen was employed at Hutchinson Technology Inc., from 1999 to 2010, in positions of increasing responsibility, most recently serving as Director of Engineering in the BioMedical Division. Mr. Madsen successfully led the development and commercial launch of Hutchinson’s advanced mobile sensors for monitoring tissue oxygenation. Prior to joining Hutchinson Technology, Mr. Madsen was employed by Boston Scientific Corporation, Inc. He holds a B.S. in Mechanical Engineering degree from the University of North Dakota.
Jonathan S Jaffe, M.D., Vice President of Clinical and Medical Affairs
Dr. Jaffe joined Antares Pharma in July 2012 as Vice President of Clinical Development. Immediately prior to joining Antares, Dr Jaffe served on a consulting basis for Pharmanet-i3 as a clinical program leader in inflammatory bowel disease in Pfizer’s Bio-therapeutics Unit. Prior to working at Pharmanet-i3, Dr. Jaffe led global clinical development programs, conducting all phases of research, for respiratory, transplant and autoimmune indications at Schering Plough Research Institute, Novartis, and Forest Research Institute. Dr. Jaffe received a Bachelor of Arts degree in Biology from Lehigh University and an MD from the Jefferson Medical College of Thomas Jefferson University in Philadelphia. He completed a residency in Internal Medicine at Lenox Hill Hospital, followed by clinical and laboratory fellowships at the Laboratory of Clinical Investigation, NIAID, NIH, while in the Research Officers Group of the Public Health Service. Following fellowship, Dr Jaffe served on the full-time academic faculty of Hahnemann (now Drexel) University Medical School where he conducted research, taught in the clinics and provided medical care. His work on clinical development programs has resulted or contributed to multiple regulatory approvals of compounds both in the US and abroad including Rapamune, Remicade, Xolair, Zortress, and Daliresp.
Keith Muckenhirn, Principal Financial Officer and Principal Accounting Officer
Keith Muckenhirn is currently the Principal Financial Officer and Principal Accounting Officer. He joined the Company in March 2001 as Controller. Prior to joining the Company, Mr. Muckenhirn served as Financial Reporting Manager from November 1994 to March 2001 at Musicland Stores Corporation, a billion dollar retailer of home-entertainment products. From January 1986 to November 1994 Mr. Muckenhirn held various positions of increasing responsibility in the public accounting field. He became a CPA in 1987, and received a B.S. degree in accounting from the Carlson School of Management at the University of Minnesota in December 1985.
Greg DeFilippis, Vice President Business Development & Alliances
Mr. DeFilippis joined Antares in July of 2013 as Sr. Director of Business Alliances & Device Supply Chain Management. Prior to joining the Company Mr. DeFilippis served as Director of Business Development at Teva Pharmaceuticals. Prior to joining Teva, Mr. DeFilippis held increasing roles of responsibility in technical operations, supply chain and continuous improvement at Barr Labs, Pliva, Actavis and Alpharma. Mr. DeFilippis holds a B.S. in Industrial and Systems Engineering from Virginia Tech, a M.B.A. in Finance from Fairleigh Dickinson University and is a Certified Lean Six Sigma Master Black Belt.
Dr. Steven Knapp, Senior Vice President, Regulatory Affairs and Quality Assurance
Dr. Knapp is a seasoned regulatory and quality executive with over 30 years of experience in the pharmaceutical and device industry and a proven track record of building and managing regulatory and quality departments in both large and small organizations. Most recently, Dr. Knapp served as Vice President, Global Regulatory Affairs and Scientific Communications at Endo Pharmaceuticals. Prior to Endo, he was Global Vice President of Regulatory and Quality at Valeant Pharmaceuticals and served in a similar position at Ikaria. Earlier in his career, Steven spent 13 years at Bristol Myers Squibb (BMS) holding various positions of increasing responsibility in the regulatory affairs and quality assurance departments. Prior to BMS, Steve worked at Schering-Plough, in the area of International Regulatory Affairs, as well as J&J Research and Ortho Pharmaceuticals in the areas of pharmaceutical development and manufacturing. Dr. Knapp earned his Bachelor of Science in Pharmacy, Master of Science in Manufacturing/Packaging Engineering and Doctorate of Pharmacy from Rutgers University in New Brunswick, NJ.
Edward Kessig, Vice President of Sales
Mr. Kessig joined Antares in December of 2016 as the Vice President of Sales. He brings almost 25 years of Pharma experience to the company. The scope of his role includes the management and oversight of Antares’ current sales team selling Otrexup. In addition, Mr. Kessig will participate in the development of the commercial launch strategy for QST, our novel testosterone delivery device, and ultimately building out the sales team for the launch of QST. Prior to joining Antares Mr. Kessig held senior commercial roles at Lipocine as V.P. of Sales, ThromboGenics and US Commercial Head, Nuro Pharma as V.P. of Commercial Operations, Auxilium Pharmaceuticals as Senior V.P. of Sales, INOTherapeutics as North American Sales Director and various commercial roles at Elan Pharmaceuticals where he started as a sales representative in 1992.
Henry R. Wolfe, PhD, Senior Vice President Product Development.
Dr. Wolfe joined Antares Pharma in January 2017 as Senior Vice President of Pharmaceutical Development with more than 30 years of experience in the pharmaceutical and biotechnology industry. Immediately prior to joining Antares, Dr. Wolfe was Vice President of Biologics at Sun Pharma where he was responsible for the development of an NCE monoclonal antibody (tildrakizumab) in both prefilled syringe and auto-injector forms. In an earlier role at Sun, Dr. Wolfe was Vice President of Generics R&D with roles in both pharmaceutical and clinical development. Prior to its acquisition by Sun, Dr. Wolfe was Vice President of Generics R&D at URL Pharma with responsibilities for pharmaceutical development, pharmacology/toxicology and 505b2 programs. Additionally, Dr. Wolfe was the Chief Scientific Officer at two biotechnology companies (CombiMab and Genaera) focused on the development of parenteral small molecules, peptide and protein NCEs. Dr. Wolfe received a BA degree in Biology from Towson University, an MS in Biochemistry and Nutrition from Virginia Polytechnic Institute and a PhD in Molecular Pharmacology and Structural Biology from Thomas Jefferson University.